文献速递湿疹皮炎与荨麻疹

慢性荨麻疹管理策略的成本与成本效果:系统综述

Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review.
PubMed 文献 · JAMA Dermatol · 2024-01-01

本系统综述纳入17项研究(11项成本分析、6项完整经济学评价),评估慢性荨麻疹管理策略的成本与成本效果。

要点

  • 含奥马珠单抗的年度医疗成本中位数6,933美元,高于不含奥马珠单抗的5,621美元。

核心结论

  • 奥马珠单抗300 mg用于H1抗组胺药无效的CSU,在美国15万美元/QALY支付阈值下具有成本效果。
  • 无明确指征的常规实验室检查在CSU患者中不具成本效果。

研究设计与样本

  • 系统综述检索6个数据库及灰色文献,截至2024年3月23日,无语言限制。
  • 纳入17项研究:11项成本分析研究和6项完整经济学评价。
  • 两名评价者独立提取数据,货币值统一换算并膨胀至2023年美元。
  • 采用临床与经济评价研究所的证据评级矩阵判断健康获益证据。

主要发现

  • 含奥马珠单抗的医疗服务年度医疗成本估计中位数(IQR)为6,933(5,988-8,717)美元,不含奥马珠单抗为5,621(2,488-8,754)美元。

临床怎么用

  • 对H1抗组胺药无效的CSU患者,可考虑奥马珠单抗300 mg治疗,其在美国支付阈值下具有成本效果。
  • 避免对病史和体格检查正常的CSU患者进行无指征的常规实验室检查,因其不具成本效果。

局限性

  • 成本效果证据有限。
  • 需要更多样化的CU人群和资源环境中的未来研究来填补证据空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although treatment for chronic urticaria (CU) has improved over the past decades, evidence regarding costs and net benefits associated with these treatment strategies have yet to be comprehensively characterized and synthesized. OBJECTIVE: To summarize the cost and cost-effectiveness of CU management strategies. EVIDENCE REVIEW: An extensive systematic literature search of 6 databases (MEDLINE, Embase, PubMed Cochrane, Scopus, and CINAHL) and gray literature sources, without language restriction, was conducted and updated to March 23, 2024. Articles that performed cost analysis or full economic evaluation among patients with CU were included. Two reviewers independently extracted data, such as annual costs of health care services or incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY). All monetary values were converted and inflated to 2023 US dollars. Evidence-based synthesis for health benefit was judged using the Evidence Rating Matrix by the Institute for Clinical and Economic Review. FINDINGS: Seventeen unique studies (11 cost analysis studies and 6 full economic evaluations) were included. With the wide variation in health care resources, services that included biologic omalizumab utilization had higher annual health care cost estimations for CU management than services that did not include omalizumab prescription (median [IQR] cost, $6933 [$5988-$8717] vs $5621 [$2488-$8754]). The biologic omalizumab, 300 mg, for H1 antihistamine-refractory chronic spontaneous urticaria (CSU) (3 studies) was found to have a median (IQR) ICER of $89 005 ($36 058-$145 694) per QALY (evidence rating as incremental or better; moderate certainty with substantial net health benefit). Routine laboratory testing among patients with CSU with otherwise normal histories and physical examination findings (1 study) had ICERs ranging from $1 427 928 to $1 950 524 per QALY (evidence rating as comparable or inferior; moderate certainty that the net health benefit is inferior). CONCLUSIONS AND RELEVANCE: With limited evidence of cost-effectiveness, biologic omalizumab, 300 mg, for H1 antihistamine-refractory CSU was found to be cost-effective in US health care services at the willingness to pay threshold of $150 000 per QALY. Meanwhile, routine laboratory testing among patients with CSU without compelling indication was not cost-effective. Future studies in more diverse CU populations and resource settings are needed to fill evidence gaps.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Nochaiwong S, Chuamanochan M, Ruengorn C, et al. Cost and Cost-Effectiveness of the Management Strategies of Chronic Urticaria: A Systematic Review. JAMA Dermatol. 2024. PMID: 39196583. doi:10.1001/jamadermatol.2024.2863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。